INS and fatty liver disease: Current evidence is more congruent for defined consortia that restore fermentative guilds (including butyrate producers) or Akkermansia-enriched formulations that improve mucus dynamics; these products tend to produce modest, directionally favorable changes in insulin sensitivity and hepatic steatosis markers when layered on diet and weight management (59).